\
logo
  Home | Contact us | Browse | Quick Search by UniProtKB ID, Keyword, PDBID

Menu:

Latest news:

Sep. 10, 2014:
A total of 174 experimentally verified S-nitrosylation sites on 94 S-nitrosylated proteins from individualized human colorectal cancer tissues using a label-free quantitation strategy.

Read more...


Protein Name: Double-stranded RNA-specific adenosine deaminase

UniprotKB/SwissProt ID: P55265 (P55265)

Gene Name: ADAR

Organism: Homo sapiens (Human)

Function: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing (PubMed:12618436, PubMed:7565688, PubMed:7972084). This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins since the translational machinery read the inosine as a guanosine; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Cytoplasm. Nucleus. Cytoplasm. Nucleus. Nucleus, nucleolus

Graphical Visualization of S-nitrosylation Sites:
InterPro ID Domain Name
IPR002466 A_deamin
IPR044456 ADAR1_DSRM_1
IPR044457 ADAR1_DSRM_3
IPR014720 dsRBD_dom
IPR036388 WH-like_DNA-bd_sf
IPR036390 WH_DNA-bd_sf
IPR042371 Z_dom

The S-nitrosylation sites of P55265

No. Position S-nitrosylated Peptide Secondary Structure of S-nitrosylated Peptide Solvent Accessibility of nitrosylated Site PubMed ID
1 1036 RLGERLRTMS C SDKILRWNVL   
2 1224 KPQEEKNFYL C PV--------   
3 304 LDMAEIKEKI C DYLFNVSDSS   
4 392 ETKRNAEFLT C NIPTSNASNN   
5 519 LEYAQFASQT C EFNMIEQSGP   
6 622 GKSPVTTLLE C MHKLGNSCEF   
7 630 LECMHKLGNS C EFRLLSKEGP   
8 649 GPAHEPKFQY C VAVGAQTFPS   
9 851 HDQIAMLSHR C FNTLTNSFQP   
10 909 LSLKGETVND C HAEIISRRGF